{
  "_originalData": {
    "title": "Bacteroides fragilis",
    "lastUpdated": "Jan 8, 2025",
    "clinicalSetting": {
      "description": "Bacteroides fragilis group (24 species): strict anaerobic bacteria, major component of the intestinal flora.",
      "empiricTherapy": "Empiric therapy of infections involving fecal flora (e.g., secondary peritonitis due to a ruptured appendicitis, ruptured diverticulitis, ischemic bowel, a leaking surgical anastomosis among other conditions, ruptured appendix) includes a drug with activity vs. B. fragilis group bacteria as well as aerobic organisms.",
      "bloodCultures": "Blood cultures are rarely positive for Bacteroides or other strictly anaerobic bacterial pathogens. When bacteremia does occur, metastatic seeding of other body sites is documented in the absence of an obvious intestinal portal of entry (Intern Med 47:2183, 2008).",
      "susceptibilityData": "The bulk of in vitro susceptibility data is generated by, and periodically reported by, a few academic labs (Anaerobe 2017;43:21; Antimicrob Ag Chemother 56:1247, 2012). See Comments."
    },
    "classification": {
      "description": "Gram negative bacilli, strict anaerobe",
      "otherSpecies": "Other Bacteroides species are occasionally isolated (DOT species = B. distasonis (Now Parabacteroides distasonis), B. ovatus, B. thetaiotaomicron)"
    },
    "regimens": {
      "primary": [
        {
          "drug": "Metronidazole",
          "dosage": "500 mg IV/po q6-8h or 1 gm IV q12h or, in some reports, 1.5 gm IV once daily"
        },
        {
          "drug": "Piperacillin-tazobactam",
          "dosage": "4.5 gm IV (over 4 hr) q8h"
        }
      ],
      "alternative": [
        {
          "drug": "Imipenem-cilastatin",
          "dosage": "500 mg IV q6h"
        },
        {
          "drug": "Doripenem",
          "dosage": "500 mg IV q8h"
        },
        {
          "drug": "Meropenem",
          "dosage": "0.5-1 gm"
        },
        {
          "drug": "Ertapenem",
          "dosage": "1 gm IV once daily"
        },
        {
          "note": "Prolonged infusion regimens for Doripenem and Meropenem are reported. See Prolonged Infusion."
        },
        {
          "drug": "Amoxicillin-clavulanate",
          "dosage": "875/125 mg po bid for milder disease; e.g., mild diverticulitis treated as an outpatient"
        }
      ]
    },
    "antimicrobialStewardship": [
      "Due to an increasing prevalence of in vitro resistance, Clindamycin, Cefoxitin and Cefotetan are no longer recommended.",
      "Resistance to Moxifloxacin is also increasing.",
      "Virtually no, or very rare, resistance to Metronidazole, Piperacillin-Tazobactam, or the carbapenems"
    ],
    "comments": [
      "Susceptibility testing not routinely performed in most clinical micro labs.",
      "In vitro antimicrobial activity vs. B. fragilis group: Clin Infect Dis 59: 698, 2014; Anaerobe 2017;43:21.",
      "Surveys of susceptibility: Anaerobe 2017; 43:21; Antimicrob Agents Chemother 56:1247, 2012.",
      "Guidance on intra-abdominal infections: Clin Infect Dis 50:133, 2010; Surg Infections 2017; 18: 1-76."
    ]
  },
  "_metadata": {
    "originalKeys": [
      "title",
      "lastUpdated",
      "clinicalSetting",
      "classification",
      "regimens",
      "antimicrobialStewardship",
      "comments"
    ],
    "conversionTimestamp": "2025-07-15T03:16:49.250Z",
    "sourceFormat": "legacy_simple"
  },
  "identity": {
    "bacteriumName": {
      "sources": [
        "title"
      ],
      "value": "Bacteroides fragilis"
    },
    "aliases": {
      "sources": [
        "aliases"
      ],
      "value": []
    }
  },
  "clinicalInformation": {
    "sources": [
      "clinicalSetting"
    ],
    "value": {
      "description": "Bacteroides fragilis group (24 species): strict anaerobic bacteria, major component of the intestinal flora.",
      "empiricTherapy": "Empiric therapy of infections involving fecal flora (e.g., secondary peritonitis due to a ruptured appendicitis, ruptured diverticulitis, ischemic bowel, a leaking surgical anastomosis among other conditions, ruptured appendix) includes a drug with activity vs. B. fragilis group bacteria as well as aerobic organisms.",
      "bloodCultures": "Blood cultures are rarely positive for Bacteroides or other strictly anaerobic bacterial pathogens. When bacteremia does occur, metastatic seeding of other body sites is documented in the absence of an obvious intestinal portal of entry (Intern Med 47:2183, 2008).",
      "susceptibilityData": "The bulk of in vitro susceptibility data is generated by, and periodically reported by, a few academic labs (Anaerobe 2017;43:21; Antimicrob Ag Chemother 56:1247, 2012). See Comments."
    }
  },
  "treatmentData": {
    "_treatmentMetadata": {
      "originalFormat": "legacy_simple"
    },
    "standardizedRegimens": [
      {
        "regimenId": "primary-0",
        "extractedFrom": "regimens.primary[0]",
        "preference": "primary",
        "drugs": [
          {
            "drugName": "Metronidazole",
            "dose": "500 mg",
            "route": "IV/po",
            "frequency": "q6-8h",
            "originalText": "500 mg IV/po q6-8h or 1 gm IV q12h or, in some reports, 1.5 gm IV once daily"
          }
        ]
      },
      {
        "regimenId": "primary-1",
        "extractedFrom": "regimens.primary[1]",
        "preference": "primary",
        "drugs": [
          {
            "drugName": "Piperacillin-tazobactam",
            "dose": "4.5 gm",
            "route": "IV",
            "frequency": "q8h",
            "originalText": "4.5 gm IV (over 4 hr) q8h"
          }
        ]
      },
      {
        "regimenId": "alternative-0",
        "extractedFrom": "regimens.alternative[0]",
        "preference": "alternative",
        "drugs": [
          {
            "drugName": "Imipenem-cilastatin",
            "dose": "500 mg",
            "route": "IV",
            "frequency": "q6h",
            "originalText": "500 mg IV q6h"
          }
        ]
      },
      {
        "regimenId": "alternative-1",
        "extractedFrom": "regimens.alternative[1]",
        "preference": "alternative",
        "drugs": [
          {
            "drugName": "Doripenem",
            "dose": "500 mg",
            "route": "IV",
            "frequency": "q8h",
            "originalText": "500 mg IV q8h"
          }
        ]
      },
      {
        "regimenId": "alternative-2",
        "extractedFrom": "regimens.alternative[2]",
        "preference": "alternative",
        "drugs": [
          {
            "drugName": "Meropenem",
            "dose": "1 gm",
            "originalText": "0.5-1 gm"
          }
        ]
      },
      {
        "regimenId": "alternative-3",
        "extractedFrom": "regimens.alternative[3]",
        "preference": "alternative",
        "drugs": [
          {
            "drugName": "Ertapenem",
            "dose": "1 gm",
            "route": "IV",
            "frequency": "once daily",
            "originalText": "1 gm IV once daily"
          }
        ]
      },
      {
        "regimenId": "alternative-4",
        "extractedFrom": "regimens.alternative[4]",
        "preference": "alternative",
        "drugs": [
          {
            "drugName": "Unknown",
            "originalText": "{\"note\":\"Prolonged infusion regimens for Doripenem and Meropenem are reported. See Prolonged Infusion.\"}"
          }
        ]
      },
      {
        "regimenId": "alternative-5",
        "extractedFrom": "regimens.alternative[5]",
        "preference": "alternative",
        "drugs": [
          {
            "drugName": "Amoxicillin-clavulanate",
            "dose": "125 mg",
            "route": "po",
            "frequency": "bid",
            "originalText": "875/125 mg po bid for milder disease; e.g., mild diverticulitis treated as an outpatient"
          }
        ]
      }
    ],
    "narrativeTreatments": {
      "primaryRegimens": {
        "originalFormat": "object",
        "content": [
          {
            "drug": "Metronidazole",
            "dosage": "500 mg IV/po q6-8h or 1 gm IV q12h or, in some reports, 1.5 gm IV once daily"
          },
          {
            "drug": "Piperacillin-tazobactam",
            "dosage": "4.5 gm IV (over 4 hr) q8h"
          }
        ]
      },
      "alternativeRegimens": {
        "originalFormat": "object",
        "content": [
          {
            "drug": "Imipenem-cilastatin",
            "dosage": "500 mg IV q6h"
          },
          {
            "drug": "Doripenem",
            "dosage": "500 mg IV q8h"
          },
          {
            "drug": "Meropenem",
            "dosage": "0.5-1 gm"
          },
          {
            "drug": "Ertapenem",
            "dosage": "1 gm IV once daily"
          },
          {
            "note": "Prolonged infusion regimens for Doripenem and Meropenem are reported. See Prolonged Infusion."
          },
          {
            "drug": "Amoxicillin-clavulanate",
            "dosage": "875/125 mg po bid for milder disease; e.g., mild diverticulitis treated as an outpatient"
          }
        ]
      }
    }
  },
  "additionalData": {
    "antimicrobialStewardship": {
      "sources": [
        "antimicrobialStewardship"
      ],
      "value": [
        "Due to an increasing prevalence of in vitro resistance, Clindamycin, Cefoxitin and Cefotetan are no longer recommended.",
        "Resistance to Moxifloxacin is also increasing.",
        "Virtually no, or very rare, resistance to Metronidazole, Piperacillin-Tazobactam, or the carbapenems"
      ]
    },
    "comments": {
      "preservedStructure": {
        "originalFormat": "array",
        "content": [
          "Susceptibility testing not routinely performed in most clinical micro labs.",
          "In vitro antimicrobial activity vs. B. fragilis group: Clin Infect Dis 59: 698, 2014; Anaerobe 2017;43:21.",
          "Surveys of susceptibility: Anaerobe 2017; 43:21; Antimicrob Agents Chemother 56:1247, 2012.",
          "Guidance on intra-abdominal infections: Clin Infect Dis 50:133, 2010; Surg Infections 2017; 18: 1-76."
        ]
      }
    },
    "diagnosis": {
      "sources": [
        "diagnosis"
      ],
      "value": []
    },
    "allOtherKeys": {
      "antimicrobialStewardship": [
        "Due to an increasing prevalence of in vitro resistance, Clindamycin, Cefoxitin and Cefotetan are no longer recommended.",
        "Resistance to Moxifloxacin is also increasing.",
        "Virtually no, or very rare, resistance to Metronidazole, Piperacillin-Tazobactam, or the carbapenems"
      ]
    }
  }
}